Since the passage of the Inflation Reduction Act, companies, investors, and patients have raised concerns about how the legislation will impact innovation in the biotech industry. Will there be a decline in R&D for key disease areas? Are investors shifting their priorities because of future implications of price negotiations? Attend this session to learn about the latest regulatory guidance, the advocacy of BIO to address these concerns, and the strategy from leaders in the industry to prepare for the evolving landscape.